Voyager Therapeutics does not distribute cash dividends to its equity shareholders. As a clinical-stage biotechnology enterprise dedicated to researching and developing complex gene therapies for central nervous system disorders, the company channels all available financial resources back into laboratory research, vector engineering, and clinical trial pipelines. Investors purchase shares with the expectation of long-term capital appreciation driven by potential drug approvals and strategic corporate partnerships rather than regular income yields.